Mast cell tumor historical perspective

Jump to: navigation, search

Mast cell tumor Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mast Cell Tumor from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Diagnostic criteria

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT Scan

MRI

Biopsy

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mast cell tumor historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mast cell tumor historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mast cell tumor historical perspective

CDC on Mast cell tumor historical perspective

Mast cell tumor historical perspective in the news

Blogs on Mast cell tumor historical perspective

Directions to Hospitals Treating Mast cell tumor

Risk calculators and risk factors for Mast cell tumor historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]

Overview

Mast cell activation was first described by Dr. Nettleship and Tay in 1869. Dr. Sezary and other french scientists reported the first case of mast cell tumor in 1936.

Historical Perspective

Discovery

  • In 1869, Dr. Nettleship and Tay were the first ever to discuss the mast cell activation and it was in a case of urticaria pigmentosa.[1]
  • In 1936, Dr. Sézary and other french scientists reported the first case of systemic mastocytosis or mast cell tumor.
  • Dr. Sezary describes the systemic mastocytosis as aberrant mast cell proliferation which is characterized by release of immense vasoactive amines.[2]

References

  1. Scherber RM, Borate U (2018). "How we diagnose and treat systemic mastocytosis in adults". Br J Haematol. 180 (1): 11–23. doi:10.1111/bjh.14967. PMID 29048112.
  2. Scherber RM, Borate U (2018). "How we diagnose and treat systemic mastocytosis in adults". Br J Haematol. 180 (1): 11–23. doi:10.1111/bjh.14967. PMID 29048112.

Linked-in.jpg